The phase Ib PIPA trial has assessed the combination of the ß-isoform sparing PI3Ki taselisib with palbociclib in mBC, including a cohort of TNBC selected for activating PI3K mutations, reporting good tolerability and promising anti-tumor activity [86]. This evidence concerns the gene PIK3CA and neoplasm.